MYGN:NGS-Myriad Genetics Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 18.18

Change

+0.20 (+1.11)%

Market Cap

USD 1.17B

Volume

0.52M

Analyst Target

USD 15.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+6.81 (+1.43%)

USD 41.47B
ICLR ICON PLC

-0.60 (-0.19%)

USD 25.49B
ILMN Illumina Inc

-6.16 (-5.18%)

USD 19.47B
MEDP Medpace Holdings Inc

+1.36 (+0.34%)

USD 12.27B
NTRA Natera Inc

-0.06 (-0.06%)

USD 11.20B
EXAS EXACT Sciences Corporation

-1.94 (-3.06%)

USD 10.68B
RDNT RadNet Inc

+0.47 (+0.90%)

USD 3.57B
SHC Sotera Health Co

+0.18 (+1.59%)

USD 3.10B
OLK Olink Holding AB ADR

+0.07 (+0.30%)

USD 2.72B
NEOG Neogen Corporation

+0.27 (+2.22%)

USD 2.63B

ETFs Containing MYGN

HEP:CA Horizons Enhanced Income .. 0.00 % 0.83 %

N/A

CAD 0.23B
MXF:CA CI First Asset Can-Materi.. 0.00 % 0.74 %

N/A

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.02% 72% C 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.02% 72% C 43% F
Trailing 12 Months  
Capital Gain -14.61% 60% D- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.61% 60% D- 37% F
Trailing 5 Years  
Capital Gain -42.74% 55% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.74% 55% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 8.81% 57% F 68% D+
Dividend Return 8.81% 57% F 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 64.40% 41% F 25% F
Risk Adjusted Return 13.69% 63% D 52% F
Market Capitalization 1.17B 81% B- 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.00 43% 30%
Price/Book Ratio 2.56 46% 39%
Price / Cash Flow Ratio -18.58 82% 87%
Price/Free Cash Flow Ratio -10.20 87% 84%
Management Effectiveness  
Return on Equity -31.55% 63% 39%
Return on Invested Capital -10.26% 75% 39%
Return on Assets -7.40% 71% 37%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector